

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

1 August 2024

Appointment and Resignation of Directors

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to update shareholders with the following changes to its Board of Directors.

Appointment of Melanie Leydin as a Non-Executive Director

Ms Melanie Leydin will join the Board as a Non-Executive Director with the appointment effective from 31 July 2024.

Ms Leydin has over 25 years' experience in the accounting profession and over 15 years as a company secretary with extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, re-organisation of Companies and shareholder relations.

Resignation of Directors

IBX announces that, effective immediately before the conclusion of the General Meeting scheduled on 22 August 2024, Michael Harsh, David Ludvigson and Mark Van Astan, will cease to hold office. (That is, all of the directors who were in office at the time the directors' report (as included in the Company's annual financial report for the financial year ended 31 December 2023) was approved, other than Robert Proulx who acts as Executive Chairman and Managing Director, will cease to hold office).

Bob Proulx, Executive Chairman said, "We would like to thank Mr Michael Harsh, Mr David Ludvigson and Mr Mark Van Asten for their years of service and passion to Imagion Biosystems and wish them well for their future endeavors. We are very pleased to welcome Melanie as a Non-Executive Director of Imagion. Melanie's experience in the ASX capital markets will be very helpful as we chart our path forward."

— ENDS —





About Imagion Biosystems

Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASX-listed company dedicated to developing innovative medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense® platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI. The Company's lead program has demonstrated its innovative technology embodied in MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Imagion Biosystems' MagSense® pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs.

For more information, visit <https://imaginationbiosystems.com/investor-hub/>

Authorisation & Additional information

This announcement was authorised by the Board of Imagion Biosystems Limited.

Imagion Biosystems Ltd.

ASX:IBX ACN 616 305 027

www.imaginationbiosystems.com

